Saneron CCEL Therapeutics

What Saneron CCEL Therapeutics does

Saneron CCEL Therapeutics is a privately held biotechnology research and development company headquartered in Clearwater, Florida. The firm operates with a small team of 1-10 employees and is structured as a for-profit private entity with no public ticker. Its website (saneron-ccel.com) currently contains only a placeholder page, and the available source material provides no substantive disclosure of the company's specific therapeutic focus, pipeline, scientific platform, or technology stack.

Leadership is concentrated among a tight group of founders and executives: Paul R. Sanberg serves as Chief Executive Officer, with Daniel Richard, Paul R. Sanberg, and Don F. Cameron listed as co-founders. Nicole Kuzmin-Nichols holds the President and Chief Operating Officer role, and Cyndy Davis Sanberg serves as Vice President. The leadership roster suggests a founder-led operating model, though the company does not currently appear to have disclosed any commercial products, customers, partnerships, regulatory milestones, or capital-raising events in the available data.

Given the absence of disclosed products, revenue, funding rounds, patents, partnerships, customer relationships, or regulatory actions in the source material, the company's commercial status, monetization model, and go-to-market strategy cannot be characterized from the input. At minimum, Saneron CCEL Therapeutics presents as a small, privately held biotech entity whose operational footprint and strategic posture cannot be further specified without additional primary-source information beyond what is currently available.

Name

Saneron CCEL Therapeutics

Legal name

Saneron CCEL Therapeutics

Website

https://saneron-ccel.com

Company type

Private

Headcount range

1–10 employees

Short description

Saneron CCEL Therapeutics is a privately held biotechnology research and development company based in Clearwater, Florida, with 1-10 employees and a founder-led leadership team focused on cell-based therapeutic research.

Ownership category

akta.pro rank

Product category

Cell-Based Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industry

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

• Cell therapy research
• Regenerative medicine
• Biotechnology R&D
• Cell-based therapeutics
• Stem cell therapies

Headquarters

HQ city

Clearwater

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Saneron CCEL Therapeutics is a privately held biotechnology research and development company operating in the cell-based therapeutics space. The company conducts research in regenerative medicine, focusing on cellular product development for therapeutic applications. Its work centers on cryopreserved cell-based technologies intended for eventual clinical and commercial use in treating disease.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights2 records

Direct peers

• BrainStorm Cell Therapeutics: Clinical-stage cell therapy developer focused on autologous neurotrophic factor-secreting cell therapies for neurodegenerative diseases (ALS, MS, Parkinson's). Directly comparable to Saneron as a small-cap CNS cell therapy R&D company.
• Capricor Therapeutics: Develops cell-derived exosome and allogeneic cardiosphere-derived cell therapies, including programs targeting Duchenne muscular dystrophy and COVID-related indications. Comparable small public biotech in cell-based therapeutics for serious diseases.
• Athersys (now Healios KK for MultiStem): Developed MultiStem, a multi-stem cell therapy platform with neurological and inflammatory indications (stroke, ARDS). Directly comparable cell therapy platform targeting CNS indications.
• Cytori Therapeutics: Cell therapy company developing adipose-derived regenerative cell therapies. Comparable small-cap biotech pursuing cell-based therapeutics with a focus on regenerative medicine.
• Pluristem Therapeutics: Develops placenta-derived allogeneic cell therapy products (PLX cells) for inflammatory, ischemic, and hematological conditions. Directly comparable as a small-cap allogeneic cell therapy developer.
• Neuralstem (acquired by Summit Therapeutics): Was a neural stem cell therapy developer for ALS and other CNS indications. Highly comparable in focus on cell-based therapies for neurological diseases; provides a template of the acquisition pathway for similar small-cap cell therapy firms.

Broad incumbents

• Mesoblast: Larger commercial-stage allogeneic cellular medicines company with mesenchymal lineage platforms across multiple indications including heart failure and inflammatory conditions. Comparable cell therapy approach but at meaningfully greater scale.

Others

• Cryo-Cell International: Umbilical cord blood banking company historically linked to the CCEL lineage. Comparable as a related cord blood cell ecosystem participant and potential source/manufacturing partner for Saneron's therapeutic cells.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Saneron CCEL Therapeutics